WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: (11) International Publication Number: WO 93/15766 **A**1 A61K 45/05, 39/00, 37/02 (43) International Publication Date: 19 August 1993 (19.08.93)

(21) International Application Number: PCT/US93/01034 (81) Designated States: AU, CA, FI, JP, KR, NO, NZ, Euro-(22) International Filing Date: 4 February 1993 (04.02.93)

(30) Priority data: 832,843 10 February 1992 (10.02.92)

(71) Applicant: SERAGEN, INC. [US/US]; 97 South Street. Hopkinton, MA 01748 (US).

(72) Inventors: WATERS, Cory, Ann; 12 Clark Road, Bedford, MA 01730 (US). NICHOLS, Jean, C.; 15 Astra Way, Wayland, MA 01778 (US).

(74) Agent: CLARK, Paul, T.; Fish & Richardson, 225 Franklin Street, Boston, MA 02110 (US).

pean patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

(54) Title: DESENSITIZATION TO SPECIFIC ALLERGENS

(57) Abstract

A method for desensitizing an animal to a particular allergen, wherein at or about a time of exposure of the animal to the allergen, a molecule is administered to the animal, which molecule is characterized in that it specifically binds under physiological conditions to an interleukin-4 (IL-4) receptor expressed on a peripheral blood mononuclear cell (PBMC) of the animal, and is capable of decreasing the viability of the PBMC to which it binds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania	
AU	Australia	GA	Gabon	MW	Malawi	
BB	Barbados	GB	United Kingdom	NL	Netherlands	
BE	Belgium	GN	Guinea	NO	Norway	
BF	Burkina Faso	GR	Greece	NZ	New Zealand	
BG	Bulgaria	HU	Hungary	PL	Poland	
BJ	Benin	1E	Ireland	PT	Portugal	
BR	Brazil	IT -	Italy	RO	Romania	
CA	Canada	JP	Japan	RU.	Russian Federation	
CF .	Central African Republic	KP -	Democratic People's Republic	SD	Sudan	
CG	Congo		of Korea	SE	Sweden	
CH	Switzerland	KR -	Republic of Korea	SK	Slovak Republic	
CI	Côte d'Ivoire	KZ -	Kazakhstan	SN	Senegal	
CM	Cameroon	LI	Liechtenstein	SU	Soviet Union	
CS	Czechoslovakia	LK	Sri Lanka	TD	Chad	
CZ	Czech Republic	LU	Luxembourg	TG	Togo	
DE	Germany	MC	Monaco	UA	Ukraine	
DK	Denmark	MC	Madagascar	US	United States of America	
ES	Spain	Ml.	Mali	VN	Viet Nam	
FI	Finland	MN	Mongolia			

DESENSITIZATION TO SPECIFIC ALLERGENS

Background of the Invention

The field of the invention is prevention and 5 treatment of allergies.

An allergy is an immunological reaction, generally of the immediate hypersensitivity type, to a particular type of antigen termed an allergen. Such reactions underlie attacks of anaphylaxis, allerigic rhinitis (hay 10 fever), hives, and allergic asthma, and may be triggered by common allergens such as ragweed, pollen, bee or wasp venom, animal dander, mold, or a component of house dust (such as mites). In humans, immediate hypersensitivity (IH) is mediated by antibodies of the IgE isotype 15 anchored to the surfaces of mast cells and basophils in the skin and elsewhere. Binding of antigen to these cell-bound IgE molecules triggers release of mediators such as histamine from the cells, which mediators induce the clinical phenomena such as tissue swelling, itching, 20 or bronchial smooth muscle contraction that typify an allergic reaction.

IgE antibodies specific for a given allergen are produced and secreted by B lymphocytes upon contact with that allergen. Initially, B lymphocytes (or B cells)

25 express antibodies of the IgM isotype, with each B cell committed to producing antibody specific for a particular antigenic determinant. Contact with both an allergen bearing that antigenic determinant, and certain factors produced by T lymphocytes, will induce the B cell to

30 undergo what is termed an antibody heavy chain class switch, in which the antigen-specific portion of the antibody produced by the B cell remains the same, but it is attached to ε-heavy chain (to yield IgE antibody) rather than the μ-heavy chain of the IgM isotype. Such a class switch is apparently permanent for a given B cell,

- 2 -

which thereafter secretes IgE antibody specific for the allergen whenever stimulated to do so. One of the factors which has been shown to be involved in this class switch event is interleukin-4 (IL-4) (Lebman and Coffman, J. Exp. Med. 168:853, 1988), a 20kD protein produced by T lymphocytes. Human IL-4 has been cloned and sequenced by Yodota et al. (Proc. Natl. Acad. Sci. USA 83: 58994, 1986).

Common treatments for allergy include avoidance of the suspected allergen; injections of the allergen as immunotherapy to stimulate certain protective mechanisms and thereby eventually desensitize the host to the allergen; drugs such as corticosteroids, which interfere with the release of the mediators of allergy from mast cells; and drugs such as antihistamines, which block the biological action of the released mediators.

Summary of the Invention

It has now been found that, by treating B cells which have not yet undergone the class switch from IgM 20 production to IgE production with a cytotoxic compound (such as the recombinant protein referred to as DAB389IL-4) that binds to IL-4 receptors on such cells, the production of IgE by such cells following exposure to an allergen analog (αCD40 MAb) can be prevented. 25 contrast, production of IgE by B cells that have previously switched isotypes is only slightly inhibited by treatment with such an IL-4R-targeting cytotoxic compound, and only by very high levels of the compound. It is believed that the mechanism by which this occurs is 30 as follows: those IgM-expressing B cells which are stimulated by allergen to begin the process of class switching first express a temporarily increased number of IL-4 receptors on their surfaces, which render the cells more likely to bind molecules of an IL-4R-targeted

cytotoxin. Like IL-4 itself, the IL-4R-targeted cytotoxin causes the receptor to which it binds to be internalized by the cell, carrying the cytotoxin, along with the receptor to which it is bound, into the vesicle 5 so formed. The cytotoxic portion of the compound then exits the vesicle and enters the cytoplasm of the cell, where it enzymatically inactivates a crucial cellular protein synthesis factor. With protein synthesis shut off, IgE cannot be made, nor will the cell survive long: 10 thus, any B cells induced by an allergen to undergo a class switch are selectively disabled or killed, leaving only previously-switched B cells to produce IgE in response to the allergen. Furthermore, treatment with a cytotoxin that targets receptors such as IL-4R, IL-2R, or 15 IL-6R provides another mechanism of reducing IgE production, by killing or disabling those peripheral blood mononuclear cells (PBMC's) which are activated in the presence of the allergen to produce factors such as cytokines which stimulate IgE production by B cells. The 20 invention therefore features a method for desensitizing an animal to a particular allergen, whereby in need of such desensitization is first identified, and at or about a time of exposure of the animal to the allergen, a molecule is administered to the animal which 25 specifically binds under physiological conditions to an IL-4 receptor expressed on a PBMC (preferably a B cell), of the animal, the molecule being capable of decreasing the viability of the PBMC (i.e., the molecule is inherently able to contribute to the death or temporary 30 disablement of a PBMC to which it binds via an IL-4 receptor): preferably, the molecule, following binding to an IL-4 receptor, kills the PBMC to which it has bound. The "exposure" referred to may be a result of deliberately administering the allergen to the patient 35 (e.g., by injection), or the patient's having

- 1 -

inadvertantly or intentionally come in contact with an environmental source of the allergen outside of a clinical setting (e.g., by inhaling ragweed during hay fever season, by holding a pet the dander of which is 5 allergenic, or by receiving a bee sting). effective, the IL-4R-targeted cytotoxin must be administered at or about the time of (i.e., just prior to, contemporaneously with, or soon after) exposure of the subject animal to the allergen of interest, to ensure 10 that most or all of the animal's allergen-stimulated, unswitched B cells and other PBMCs will bear their temporarily heightened levels of IL-4 receptors during the period that the cytotoxin is present in the animal's bloodstream. Administration of the cytotoxin may be 15 continued even after contact with the allergen has ceased, to ensure that all susceptible B cells are ultimately prevented from making the isotype switch, and/or that other IL-4R-bearing PBMCs in the animal are prevented from contributing to the IgE-secretion process. 20 Because at any time new B cells may arise which have the potential of being triggered into switching isotype by the allergen, the treatment is preferably repeated on a regular basis.

The animal is preferably a mammal such as a mouse or a dog, and most preferably is a human patient who is either naive (i.e., has never previously been exposed to the allergen of interest, or at least never in a manner sufficient to trigger an immunogenic response), or is atopic (i.e., has demonstrated an allergic response to this or a related allergen in the past). Thus, the term "desensitization" refers not only to the method as applied to atopic individuals, but also as the method is applied to anyone, even naive subjects, who may be treated prophylactically in order to ensure they never develop an allergy to the given allergen. Such

prophylactic treatment would be of particular benefit to children of atopic parents, who run a greatly increased risk, compared to the children of non-atopic parents, of eventually developing allergies.

5 In preferred embodiments, the molecule used in the method of the invention is a hybrid molecule (such as a polypeptide) having a first and a second portion joined together covalently, the first portion including a moiety capable of decreasing cell viability and the second 10 portion including a moiety capable of specifically binding to an IL-4 receptor on a PBMC under physiological conditions [i.e., upon contact with such an IL-4 receptor under physiological conditions, the moiety binds to IL-4 receptors and does not bind detectably to any other 15 structure found on the surfaces of PBMC's from the same species]. By "under physiological conditions" is meant in blood or serum, or in an aqueous solution such as phosphate-buffered saline that approximates the pH and salt conditions which occur in blood in vivo. The IL-4R-20 binding moiety may be, for example, IL-4, an IL-4Rbinding portion of IL-4, an IL-4R-binding monoclonal antibody, or an IL-4R-binding portion of such a monoclonal antibody. Where the animal to be treated is a human, the moiety is preferably human IL-4.

The "first portion" of the hybrid molecule preferably includes an enzymatically-active segment of a polypeptide toxin such as diphtheria toxin, Pseudomonas exotoxin A, ricin, Shiga toxin, Shiga-like toxin-I, Shiga-like toxin II, Shiga-like toxin II, Shiga-like toxin II, Shiga-like toxin II, Salmonella LT, cholera toxin, C3 toxin, pertussis toxin, tetanus toxin, abrin, modeccin, volkensin, viscumin, alorin, saporin, or gelonin, and more preferably includes fragment A of diphtheria toxin and a portion of fragment B of diphtheria toxin, but does not possess a generalized eukaryotic cell-binding activity such as is found on

- 6 -

fragment B of diphtheria toxin and many other toxins.

Most preferably, the toxin segment is DAB₃₈₉ or DAB₄₈₆,
and the hybrid molecule is DAB₃₈₉IL-4 or DAB₄₈₆IL-4.

Treatment with such an IL-4R-binding cytotoxin may

5 optionally be accompanied by administering to the animal a second cytotoxic molecule which specifically binds under physiological conditions to an interleukin-2 (IL-2) or interleukin-6 (IL-6) receptor on the same PBMC as is bound by the IL-4R-binding cytotoxin, or on a different

10 PBMC (monocyte, T cell or B cell). Such ancillary treatment may help minimize the level of IgE production resulting from contact with the allergen.

Also within the invention is a method for inhibiting the antibody heavy-chain class switching of a 15 B cell by treating a B cell which has not yet undergone class switching with a molecule which is capable of specifically binding to an IL-4 receptor expressed on the surface of the B cell, the molecule being capable of decreasing the viability of the B cell (i.e., the 20 molecule possesses the inherent capacity to contribute to the disablement or death of a B cell to which it binds via an IL-4 receptor). This method may be carried out in vitro, using a biological sample such as blood or purified B cells, or in vivo, such as in a human patient. 25 It is preferentially accompanied by the additional step of contacting the B cell with an allergen at or about the same time as the treatment step (i.e., shortly before, during, or soon after the treatment step). used may be any of the cytotoxic IL-4R-binding hybrid 30 molecules discussed herein, but is preferably a diphtheria toxin-based recombinant polypeptide such as DAB389IL-4.

By selectively killing or disabling B cells poised to switch to the IgE isotype upon contact with a given 35 allergen, the method of the invention provides an

- 7 -

effective means of desensitizing individuals to that allergen. For those who suffer from allergies, preventing such class switching may result in a gradually decreased allergic response to the allergen as existing IgE and IgE-producing cells are naturally turned over without being replaced by newly-switched B cells. Naive individuals desensitized to a given allergen in accordance with the method of the invention may never develop an allergy to that allergen.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

Detailed Description

The drawing is first described.

15 Drawing

10

Fig. 1 is a representation of the amino acid sequence of DAB₃₈₉IL-4 and a DNA sequence encoding this hybrid protein (SEQ ID NO: 1).

<u>IL-4-receptor-targeted toxins</u>

20 The compounds useful in the method of the invention preferably contain toxic moieties, such as bacterial polypeptide toxins or enzymatically-active portions thereof, which are significantly cytotoxic only when present intracellularly. Of course, under these circumstances, the molecule must be able to enter a cell bearing the targeted IL-4 receptor (IL-4R). This may be accomplished by including on the toxin molecule a ligand (such as IL-4 itself, or a portion of IL-4 capable of binding to the IL-4 receptor, or an anti-IL-4R antibody) which, upon binding to the receptor, induces the internalization of the receptor and anything bound to it. Such an IL-4R-binding moiety can be linked to the toxin molecule chemically, using standard chemical conjugation

techniques. Alternatively, the linkage can be accomplished by engineering a hybrid recombinant DNA molecule which encodes both the IL-4R-binding moiety and the toxin in a single polypeptide. The latter approach ensures consistency of composition.

Many peptide toxins have a generalized eukaryotic receptor binding domain; in these instances the toxin must be modified to prevent intoxication of non-IL-4R-bearing cells. Any such modifications must be made in a 10 manner which preserves the cytotoxic functions of the molecule. Potentially useful polypeptide toxins include, but are not limited to: diphtheria toxin, Pseudomonas exotoxin A, cholera toxin, ricin, Shiga toxin, the Shigalike toxins (SLT-I, SLT-II, SLT II_V), E. coli LT, 15 Salmonella LT, C3 toxin, pertussis toxin, tetanus toxin, abrin, modeccin, volkensin, viscumin, alorin, saporin, and gelonin.

Other types of toxic moieties which may be linked to an IL-4R-binding ligand for use in the method of the invention include, for example, radionuclides and cancer chemotherapeutic agents.

Diphtheria Toxin-based Molecules

Diphtheria toxin, which is described in detail in Murphy U.S. Patent No. 4,675,382 (hereby incorporated by reference), can be used to produce molecules useful in the method of the invention. The natural diphtheria toxin molecule secreted by Corynebacterium diphtheriae consists of several functional domains which can be characterized, starting at the amino terminal end of the molecule, as fragment A (amino acids Gly₁ - Arg₁₉₃), which is the enzymatically-active portion of the protein, and fragment B (amino acids Ser₁₉₄ - Ser₅₃₅), which includes a translocation domain and a generalized cell binding domain (amino acid residues 475 through 535).

The process by which diphtheria toxin intoxicates sensitive eukaryotic cells involves at least the following steps: (i) the binding domain of diphtheria toxin binds to specific receptors on the surface of a 5 sensitive cell; (ii) while bound to its receptor, the toxin molecule is internalized into an endocytic vesicle; (iii) either prior to internalization, or within the endocytic vesicle, the toxin molecule undergoes a proteolytic cleavage between fragments A and B; (iv) as 10 the pH of the endocytic vesicle decreases to below 6, the toxin crosses the endosomal membrane, facilitating the delivery of fragment A into the cytosol; (v) the catalytic activity of fragment A (i.e., the nicotinamide adenine dinucleotide - dependent adenosine diphosphate 15 (ADP) ribosylation of the eukaryotic protein synthesis factor termed "Elongation Factor 2") causes the death of the intoxicated cell. It has been shown that a single molecule of fragment A introduced into the cytosol is sufficient to shut down the cell's protein synthesis 20 machinery, thereby killing the cell. The mechanism of cell killing by Pseudomonas exotoxin A, and possibly by certain other naturally-occurring toxins, is the same.

DAB₃₈₉IL-4, a genetically engineered fusion protein in which the receptor binding domain of
25 diphtheria toxin has been replaced by human IL-4, is an example of a molecule useful in the method of the invention. This molecule selectively kills IL-4R-expressing cells, including lymphocytes and certain tumor cells. DAB₃₈₉IL-4 is a chimeric molecule consisting of
30 (from the amino to the carboxy terminus) Met followed by amino acid residues 1 through 386 of mature diphtheria toxin, followed by a His-Ala dipeptide, followed by all of the amino acid residues of IL-4. Thus, DAB₃₈₉IL-4 includes all of diphtheria toxin fragment A (the

portion of fragment B. The portion of fragment B present in DAB₃₈₉IL-4 does not include the generalized receptor binding domain of diphtheria toxin, but does include the translocation domain which facilitates delivery of the enzymatically active portion into the cytosol.

Preparation of DAB389IL-4

A synthetic gene encoding human interleukin-4 was synthesized (Milligen/Biosearch 7500 DNA synthesizer). The IL-4 sequence (Yodota et al., Proc Nat'l Acad Sci.

10 USA, 83:58994, 1986) was modified to incorporate E. colipreferred codon usage (deBoer et al., in Maximizing Gene Expression, Reznikioff et al., eds., 1986, Butterworths, Boston), and restriction endonuclease cleavage sites were added to facilitate subsequent cloning steps. IL-4 coding sequence (His¹ to Ser¹29) was inserted into pSE5 plasmid (Shaw et al., J. Biol. Chem. 266:21118, 1991). The DNA sequence and corresponding amino acid sequence of this hybrid gene are shown in Fig. 1 (SEQ ID NO: 1). Following expression of DAB389IL-4 in E.coli, the fusion protein was purified by standard techniques.

Alternatively, the portion of diphtheria toxin utilized in the hybrid toxin can be longer or shorter than DAB₃₈₉, provided that the portion used contains the enzymatically active domain and the translocation domain of diphtheria toxin, and does not contain a functional generalized eukaryotic cell-binding domain of the naturally-occurring toxin. For example, a portion containing amino acids 1 to 485 of diphtheria toxin has been incorporated into certain toxin hybrids (where the cell-binding function is supplied by a ligand such as IL-2 or α -MSH), and the resulting hybrid polypeptide has been found to intoxicate and kill cells bearing receptors for that ligand. It would therefore be expected that this 485-amino acid segment of diphtheria toxin, as well

as many others containing longer or shorter portions of fragment B sequence, would provide the necessary functions of diphtheria toxin without the undesired generalized cell-binding function of the naturally5 occurring toxin molecule.

Yet another strategy for preparing the toxin portion of the hybrid would be to inactivate the receptor-binding domain of diphtheria toxin by, for example, making point mutations or internal deletions

10 within this domain that inhibit the toxin's ability to bind to its natural receptor (Greenfield et al., Science 238:536, 1987).

Other Toxins

The cytotoxic portion of hybrid molecules useful 15 in the invention can alternatively be provided by another type of toxin molecule. For example, hybrid toxins containing the enzymatically-active and translocation domains of Pseudomonas exotoxin A linked to IL-4 (or another IL-4R-binding ligand) can be produced by 20 recombinant techniques in a manner analogous to that described by Chaudhary et al. (Proc. Natl. Acad. Sci. USA 84:4538-4542, 1987) for a Pseudomonas exotoxin A/TGF- α The cell-binding regions of other toxins, including ricin, cholera toxin, E. coli LT, Salmonella 25 LT, Shiga toxin, the Shiga-like toxins, abrin, modeccin, volkensin, and viscumin, have been shown to be located on subunits separate from those bearing the enzymaticallyactive or effector regions of these molecules, and so can be deleted from the toxin either by such standard means 30 as genetic engineering or reduction of the disulfide bonds linking the subunits of a given toxin. these toxins (cholera toxin and the LTs) do not typically kill the cell they intoxicate, but rather disable the cell temporarily by interfering with normal regulation of

- 12 -

cyclic adenosine monophosphate (cAMP) production. Thus, the use in the method of the invention of hybrid molecules that employ the effector regions of these particular toxins may be of benefit where temporary disablement, rather than killing of the target B cell, is desired.

The DNA and/or amino acid sequences corresponding to some of these naturally-occurring toxins have been published [e.g., Shiga toxin (Strockbine et al., J. 10 Bacteriol. 170:1116-1122, 1988); SLT-II (Jackson et al., FEMS Microbiol. Lett. 44:109-114, 1987); cholera toxin (Mekalanos et al., Nature 306:551-557, 1983); and E. coli LT (Spicer and Noble, J. Biol. Chem. 257:5716-5721, 1982), all of which are hereby incorporated by reference], and the sequences of others can be determined by standard cloning and sequencing techniques well known to those of ordinary skill in the art.

Another source of the toxic portion of the IL-4R-targeted toxin is what is herein termed a "combination"

toxin. A combination toxin is a molecule having a portion of its amino acid sequence derived from one polypeptide toxin and another portion derived from a different polypeptide toxin. The combination toxins useful in the invention would have an enzymatically active domain derived from one type of naturally-occurring toxin, a translocation domain derived from another type of toxin, and a functional cell-binding domain derived from neither; the IL-rR-binding ligand would supply the only cell-binding function of this hybrid molecule.

Naturally-occurring proteins which are known to have a translocation domain include diphtheria toxin,

Pseudomonas exotoxin A, and possibly other peptide toxins. The translocation domains of diphtheria toxin and Pseudomonas exotoxin A are well characterized (see,

e.g., Hoch et al., Proc. Natl. Acad. Sci. USA 82:1692, 1985; Colombatti et al., J. Biol. Chem. 261:3030, 1986; and Deleers et al., FEBS Lett. 160:82, 1983), and the existence and location of such a domain in other molecules may be determined by methods such as those employed by Hwang et al. Cell 48:129, 1987; and Gray et al. Proc. Natl. Acad. Sci. USA 81:2645, 1984).

One useful IL-4/mixed toxin hybrid molecule is formed by fusing the enzymatically active A subunit of E. 10 coli Shiga-like toxin (Calderwood et al., Proc. Natl. Acad. Sci. USA 84:4364, 1987) to a portion of fragment B of diphtheria toxin that includes a proteolyticallysensitive disulfide loop and the translocation domain (amino acid residues 186 through 386) of diphtheria 15 toxin, and to IL-4. This three-part hybrid molecule, SLT-A/DTB'/IL-4, is useful in the method of the invention in the same way as DAB389IL-4 described above. portion of the three-part hybrid causes the molecule to attach specifically to IL-4R-bearing cells, and the 20 diphtheria toxin translocation portion participates in the insertion of the enzymatically-active A subunit of the Shiga-like toxin into the targeted cell. enzymatically active portion of Shiga-like toxin, like diphtheria toxin, acts on the protein synthesis machinery 25 of the cell to prevent protein synthesis, thus killing the cell. The difference between these two types of hybrid toxins is the nature of their enzymatic activities: the enzymatic portion of DAB389IL-4 catalyzes the ADP-ribosylation by nicotinamide adenine dinucleotide 30 of Elongation Factor 2, thereby inactivating this factor which is necessary for protein synthesis, while the enzymatic portion of SLT-A/DTB'/IL-4 is a ribonuclease capable of cleaving ribosomal RNA at a critical site, thereby inactivating the ribosome. SLT-A/DTB'/IL-4 35 hybrid would therefore be useful as a treatment for the

- 14 -

same indications as DAB₃₈₉IL-4, and could be substituted or used in conjunction with it if, for example, a patient's B cells develop a resistance to DAB₃₈₉IL-4.

Other IL-4R-binding ligands

The hybrid toxin useful in the method of the 5 invention may employ as the IL-4R-binding ligand a moiety other than full-length IL-4. By deleting various portions of the DNA encoding IL-4 using standard genetic engineering techniques, fragments of IL-4 are generated 10 which can be readily tested in an assay such as that described by Waters et al. (Eur. J. Immunol. 20:485, 1990) for their ability to bind to IL-4 receptors. Alternatively, monoclonal antibodies useful in the method of the invention can be made by immunizing mice with 15 human IL-4R+ lymphocytes (e.g., using methods similar to those of Beckmann et al., J. Immunol. 144:4212-4217, 1990), fusing the murine splenocytes with appropriate myeloma cells, and screening the antibodies produced by the resultant hybridoma lines for the requisite IL-4R 20 binding properties by, for example, assaying their ability to inhibit 125 I-labeled IL-4 binding to IL-4R+ cells using the method of Mosley et al., Cell 59:335-348, 1989. Alternatively, useful antibodies may be isolated from a combinatorial library produced by the method of 25 Huse et al. (Science 246:1275, 1989).

The invention can employ not only intact monoclonal antibodies as the IL-4R-binding ligand, but also an immunologically-active antibody fragment, for example, a Fab or (Fab)₂ fragment; an antibody heavy chain; an antibody light chain; a genetically engineered single-chain Fv molecule (Ladner et al., U.S. Patent No. 4,946,778); or a chimeric antibody, for example, an antibody which contains the binding specificity of a murine antibody, but in which the remaining portions are

of human origin, or an antibody whose Fv region is genetically engineered to capture the higher binding affinity of its target receptor's natural targeting ligand.

5 Linkage of Toxins to Binding Ligands

The binding ligand and the cytotoxin of useful hybrid molecules can be linked in several ways. hybrid molecule is produced by expression of a fused gene, a peptide bond serves as the link between the 10 cytotoxin and the binding ligand. Alternatively, the last toxin and the binding ligand can be produced separately and later coupled by means of a non-peptide covalent bond, such as a disulfide bond. In this case, if the binding ligand is a protein, e.g., IL-4, the DNA encoding 15 IL-4 can be engineered to contain an extra cysteine codon in a manner analogous to that described in Murphy et al. U.S. Serial No. 313,599, hereby incorporated by reference. The cysteine must be positioned so as to not interfere with the IL-4R binding activity of the hybrid 20 molecule. For example, the cysteine codon can be inserted just upstream of the DNA encoding the mature form of IL-4. The toxin molecule must be derivatized with a sulfhydryl group reactive with the cysteine on the modified IL-4. In the case of a peptide toxin, this can 25 be accomplished by inserting an extra cysteine codon into the DNA sequence encoding the toxin. Alternatively, a sulfhydryl group, either by itself or as part of a cysteine residue, can be introduced using known synthetic techniques. For example, the introduction of sulfhydryl 30 groups into peptides is described by Hiskey (Peptides 3:137, 1981). Derivatization can also be carried out according to the method described for the derivatization of a peptide hormone in Bacha et al. U.S. Patent No. 4,468,382, hereby incorporated by reference.

- 16 -

introduction of sulfhydryl groups into proteins is described in Maasen et al. (Eur. J. Biochem. 134:32, 1983). Once the correct sulfhydryl groups are present, the cytotoxin and IL-4R-binding ligand are separately purified; both sulfur groups are reduced; cytotoxin and ligand are mixed (in a ratio of about 1:5 to 1:20); and disulfide bond formation is allowed to proceed to completion (generally 20 to 30 minutes) at room temperature. The mixture is then dialyzed against phosphate buffered saline to remove unreacted ligand and toxin molecules. Sephadex chromatography or the like is then carried out to separate on the basis of size the desired toxin-ligand conjugates from toxin-toxin and ligand-ligand conjugates.

15 Assays for IL-4 Receptor Binding

The IL-4R binding activity of various molecules can be measured using the assay described by Park et al. (*J. Exp. Med.* 166:476, 1987) or the assay described by Foxwell et al. (*Eur. J. Immunol.* 19:1637, 1989).

20 Assays for Toxicity

Toxicity towards IL-4R bearing cells in general can be tested as follows. Cultured HUT 102/6TG cells (Tsudo et al., Proc. Natl. Acad. Sci. USA 83:9694, 1986) or MLA144 cells (Rabin et al. J. Immunol. 127:1852, 1981) 25 are maintained in RPMI 1640 medium (Gibco, Grand Island, NY) supplemented with 25 mM HEPES (pH 7.4), 2mM 1-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10% fetal calf serum (Hazelton, Lenexa, KS). Cells are seeded in 96-well V-bottomed plates (Linbro-Flow Laboratories, McLean, VA) at a concentration of 1 x 10⁵ per well in complete medium. Putative toxins are added at varying concentrations (10⁻¹²M to 10⁻⁶M) and the cultures are incubated for 20 hrs. at 37°C in a 5% CO₂

atmosphere. Following incubation, the plates are centrifuged for 5 min. at 170 x g, and the medium removed and replaced with 100 µl leucine-free medium (MEM, Gibco) containing 8 µCi/ml (³H-leucine; New England Nuclear, 5 Boston, MA). After an additional 90 min. at 37°C, the plates are centrifuged for 5 min. at 170 x g, the medium is removed, and the cells are collected on glass fiber filters using a cell harvester (Skatron, Sterling, VA). Filters are washed, dried, and counted according to 10 standard methods. Cells cultured with medium alone serve as the control. Effective cell killing is indicated by a decrease in ³H-leucine incorporation in test samples, compared to control samples which do not contain the toxin.

15 Assay for ability to prevent class-switching of B cells Materials and Methods

Interleukins and Antibodies. Human rIL-4 was used in a purified form (specific activity: 1.2 x 10⁷ U/mg). Anti-Leu-4 (IgG1 anti-CD3), anti-Leu-3a (IgG1 anti-CD4), 20 and Leu-2a (IgG1 anti-CD8), as well as the appropriate isotype controls, were obtained from Becton Dickinson & Co. (Mountain View, CA). F(ab¹)₂ fragments of monoclonal antibody 626.1 (IgG₁ anti-CD40) were obtained as described in Gruber et al., J. Immuno. 142:4144 (1989). 25 OKT3 (IgG2a anti-CD3) mAb was obtained from Ortho Diagnostic Systems Inc. (Westwood, MA). mAb B1 (IgG2a anti-CD20) was obtained from Coulter Immunology (Hialeah, FL).

Cell Preparations. PBMC were isolated from
heparinized venous blood of normal nonallergic donors by
density gradient centrifugation on Ficoll-Hypaque, washed
three times in HBSS (Microbiological Associates,
Bethesda, MD) and resuspended in RPMI 1640/10% heat
inactivated FCS (HyClone Laboratories, Logan, UT)

- 18 -

supplemented with 2 mM \bar{L} -glutamine, 50 μ g/ml streptomycin and 100 U/ml penicillin (complete medium). To obtain purified B cells, T cells were removed by rosetting twice with 2-aminoethylisothiouronium bromide (AET)-treated 5 SRBC. Further T cell depletion was obtained by two cycles of lysis with anti-CD3 mAb + rabbit C (Pel-Freeze Biologicals, Inc., Rogers, AR). To remove monocytes, non-T cells in RPMI 1640/10% AB serum were adhered twice in plastic petri dishes. The resulting B cell 10 populations contained <6% CD14+ cells and <1% CD3+ cells, as determined by immunofluorescence (IF). In addition, these B cell preparations gave no proliferative response to Con A or PHA (10 μ g/ml), while they strongly proliferated upon stimulation with PMA (25 ng/ml; Sigma 15 Chemical Co., St. Louis, MO) and insolubilized anti- μ antibody (Immunobead rabbit anti-human IgM; 1µg/ml; Bio-Rad Laboratories, Richmond, CA). Cell viability, as assessed by trypan blue exclusion, was always >95%.

Cell Cultures for IgE Induction. Purified B cells (1.0 x 10⁶ cells/ml) in complete medium were cultured at 37°C in a 5% CO₂ humidified atmosphere, in the presence of rIL-4 (100 U/ml) and the various mAbs, as indicated for each experiment in Results. After 10 d, the culture supernatants were harvested and assessed by RIA for their IgE content. Control cultures for the evaluation of preformed IgE were set up in the presence of cycloheximide (100 μg/ml; Sigma Chemical Co.). Net IgE synthesis was evaluated by subtracting the IgE concentrations detected in cycloheximide-treated cultures from the IgE values found in untreated cultures.

RIA for IgE. The assay was performed in flexible flat-bottomed microtiter plates (Cooke Laboratory Products, Alexandria, VA) at room temperature as previously described (3). The wells were coated with 0.1 35 ml of a 1:1 mixture of purified anti-Fcε mAbs (7.12 and

4.15; a kind gift of A. Saxon, University of California Los Angeles, Los Angeles, CA), 2 μ g/ml in carbonatebicarbonate buffer, pH 9.6. After 16-h incubation, the wells were washed, blocked with PBS/10% horse serum (HS) 5 for 2 h, and subsequently washed three times with PBS/1% 0.1 ml of culture supernatant or different dilutions of IgE standard (Pharmacia Fine Chemicals) were then added to the wells in triplicate and incubated for 16 h in a humidified chamber. The wells were then washed one 10 time with PBS/1% HS containing 0.05% Tween 20, twice with PBS/1% HS, and finally incubated with 0.1 ml of Phadebas RAST 125 I-anti-human IgE (ND) (Pharmacia Fine Chemicals) for 6 h. The wells were then washed three times with PBS/1% HS/0.05% Tween 20 and eight times under running 15 distilled water, cut out, and counted in a gamma spectrometer (Tracor Analytic, Elk Grove Village, IL). The concentrations of IgE in the supernatants were read from the standard curve. The lower limit of sensitivity of this assay is 150 pg/ml. This assay was validated in 20 a recent multicenter collaborative assessment of the variability of IgE measurement in cell culture supernatants [Helm et al., J. Allergy Clin. Immunol. 77:880 (1986)].

Results

In the model system, purified surface-IgE-negative B cells undergo class switch to IgE production if and only if both rIL-4 and anti-CD40 monoclonal antibody are included in the cultures. When cultured alone or in the presence of either rIL-4 or anti-CD40 monoclonal antibody, these B cells fail to produce IgE. As shown in Table I, the addition of increasing concentrations of DAB₃₈₉IL-4 ablated the IgE response in these cultures in a dose-dependent manner. As long as DAB₃₈₉IL-4 was present at the initiation of the culture, IgE synthesis was inhibited in the presence of rIL-4 and anti-CD40

- 20 -

monoclonal antibody regardless of their order of addition.

Table II shows that purified B cells from an atopic donor which have already undergone an Ig class 5 switch to IgE production require neither rIL-4 nor anti-CD40 monoclonal antibody to maintain IgE production. Furthermore, DAB₃₈₉IL-4 was unable significantly to inhibit IgE production in cultures in which the class switch had already occurred, in contrast to the marked effect the hybrid toxin has on previously unswitched cells.

Table I

DAB₃₈₉IL-4 Elimates IgE Secretion by B cells Undergoing
Ig Class Switching

	Culture	conditions	IgE	(pg/n	11)
5	rIL-4	alone (1 x 10 ⁶ ml) (100 U/ml) b (F[ab]' ₂ , 5 μ g/ml)	2 2 ND		
	A. DAB ₃	₈₉ IL-4 for 24h, wash and add α0 -4	CD40		
10		DAB ₃₈₉ IL-4 (10 ⁻⁷ M)	1 (10 (10	-8M) -9M)	2
	4.	Medium	(10	-10M) 398	421
15	B. DAB ₃	₈₉ IL-4 and αCD40 mAb for 24h, t	then		
	1. 2. 3.	DAB ₃₈₉ IL-4 (10 ⁻⁷ M)	2 (10)	-8м) -9м)	2
20	4.	Medium	(10)	⁻⁹ M) ⁻¹⁰ M) 2584	3980
-	C. DAB ₃ beginni	₈₉ IL-4, αCD40 mAb and rIL-4 ado ng of culture	ded a	t	
25	1. 2. 3.	DAB ₃₈₉ IL-4 (10 ⁻⁷ M)	2 (10)	-8M) -9M)	2
	4.	Medium	(10)	-10 _M) 1372	169

- 22 -

Table II

DAB₃₈₉IL-4 Does Not Elimate IgE Secretion by B cells from an Atopic Patient Which Hav Already Undergone an Ig Class Switch

5 <u>Culture conditions</u>	<pre>IgE (pg/ml)</pre>
B cells alone $(1 \times 10^6 \text{ml})$	34,446
rIL-4 (100 U/ml)	30,338
CD40 mAb (F[ab]' ₂ , 5 μ g/ml)	29,119

A. DAB $_{389}$ IL-4 for 24h, wash and add αCD40 10 mAb+rIL-4

	1.	$DAB_{389}IL-4 (10^{-7}M)$	20,188	
	2.	303	$(10^{-8}M)$	27,646
	3.		$(10^{-9}M)$	30,470
	4.		$(10^{-10}M)$	28,659
15	5.	Medium	28,0	78

B. DAB $_{389} IL\text{--}4$ and $\alpha CD40$ mAb for 24h, then add rIL-4

	1.	DAB389IL-4	$(10^{-7}M)$	14,064	
	2.	307		 $(10^{-8}M)$	34,237
20	3.			$(10^{-9}M)$	37,506
	4.			$(10^{-10}M)$	22,889
	5.	Medium ·		21,3	53

C. DAB $_{\rm 389}IL\text{--}4$, αCD40 mAb, rIL-4 added at beginning of culture

25	1.	$DAB_{389}IL-4 (10^{-7}M)$	14,127
	2.		$(10^{-8}M)$ 39,436
	3.		$(10^{-9}M)$ 32,052 $(10^{-10}M)$ 27,290
	4.		$(10^{-10}M)$ 27,290
	5.	Medium	29,929

Animal models

The ability of a particular hybrid IL-4R-binding toxin to diminish or ablate IgE production in vivo can be studied in an animal model such as the mouse assay 5 utilized by Urban et al. (Proc. Natl. Acad. Sci. USA 88:5513-5517, 1991), or in a species (such as dogs) known to develop allergic responses to certain allergens.

Therapy

Desensitization with the method of the invention 10 will probably be most effective if carried out on naive subjects, or on atopic subjects who are not currently mounting an allergic response. A typical protocol would involve exposing the subject animal to one or more allergens of interest (e.g., by intravenous injection) 15 simultaneously with the i.v. administration of the IL-4Rspecific toxin on day 1, followed by four more days of treatment once per day with the IL-4R-specific toxin alone. It is expected that a dosage regimen which produces a serum concentration of about 10⁻¹⁰ to 10⁻⁷M 20 DAB₃₈₉IL-4 (preferably 10^{-9} to 10^{-8} M) will effectively kill most allergen-activated B cells about to undergo an isotype class shift, without significant harm to those cells which have fewer or no IL-4 receptors. This course of treatment can be repeated several times to provide 25 effective therapy. Determination of the most efficacious treatment protocol for desensitizing a subject to a particular allergen or group of allergens using the method of the invention is within the ability of one of ordinary skill in pharmacology, using the disclosure 30 provided herein and standard pharmacological procedures. Other embodiments are within the following claims.

What is claimed is:

- 24 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

Seragen, Inc. (i) APPLICANT:

Desensitization to Specific (ii) TITLE OF INVENTION:

Allergens

(iii) NUMBER OF SEQUENCES: 1

(iv) CORRESPONDENCE ADDRESS:

Fish & Richardson (A) ADDRESSEE: 225 Franklin Street (B) STREET:

Boston (C) CITY:

Massachusetts (D) STATE:

(E) COUNTRY: U.S.A. 02110-2804 (F) ZIP:

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb (B) COMPUTER: IBM PS/2 Model 50Z or 5 IBM PS/2 Model 50Z or 55SX (B) COMPUTER: (C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30) WordPerfect (Version 5.0) (D) SOFTWARE:

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: 07/832,843

(B) FILING DATE: 10 February 1992

(viii) ATTORNEY/AGENT INFORMATION:

Fraser, Janis K. (A) NAME:

(B) REGISTRATION NUMBER: 34,819

(C) REFERENCE/DOCKET NUMBER: 00563/055W01

(ix) TELECOMMUNICATION INFORMATION:

(617) 542-5070(A) TELEPHONE: (617) 542-8906 (B) TELEFAX: 200154 (C) TELEX:

1604

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE: nucleic acid

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

								-								
ATG Met 1	GGC Gly	GCT Ala	GAT Asp	GAT Asp 5	GTT Val	GTT Val	GAT Asp	TCT Ser	TCT Ser 10	AAA Lys	TCT Ser	TTT Phe	GTG Val	ATG Met 15	GAA Glu	48
					CAC His											96
CAA Gln	AAA Lys	GGT Gly 35	ATA Ile	CAA Gln	AAG Lys	CCA Pro	AAA Lys 40	TCT Ser	GGT Gly	ACA Thr	CAA Gln	GGA Gly 45	AAT Asn	TAT Tyr	GAC Asp	144
GAT Asp	GAT Asp 50	TGG Trp	AAA Lys	GGG Gly	TTT Phe	TAT Tyr 55	AGT Ser	ACC Thr	GAC Asp	AAT Asn	AAA Lys 60	TAC Tyr	GAC Asp	GCT Ala	GCG Ala	192
GGG Gly 65	TAC Tyr	TCT Ser	GTA Val	GAT Asp	AAT Asn 70	GAA Glu	AAC Asn	CCG Pro	CTC Leu	TCT Ser 75	GGA Gly	AAA Lys	GCT Ala	GGA Gly	GGC Gly 80	240
					TAT Tyr										AAA Lys	288
GTG Asp	GAT Asn	AAT Ala	GCC Glu 100	GAA Thr	ACT Ile	ATT Lys	AAG Lys	AAA Glu 105	GAG Leu	TTA Gly	GGT Leu	TTA Ser	AGT Leu 110	CTC Thr	ACT Glu	336
GAA Val	CCG Pro	TTG Leu 115	ATG Met	GAG Glu	CAA Gln	GTC Val	GGA Gly 120	ACG Thr	GAA Glu	GAG Glu	TTT Phe	ATC Ile 125	AAA Lys	AGG Arg	TTC Phe	384
					CGT Arg										GGG Gly	432
					TAT Tyr 150										TTA Leu 160	480
AGC Ser	GTA Val	GAA Glu	CTT Leu	GAG Glu 165	ATT Ile	AAT Asn	TTT Phe	GAA Glu	ACC Thr 170	CGT Arg	GGA Gly	AAA Lys	CGT Arg	GGC Gly 175	CAA Gln	528

							CGT Arg	576
							TGG Trp	624
							GAG Glu	672
							GTA Val	720
							GCA Ala 255	768
							AAT Asn	816
							GCG Ala	864
							GCT Ala	912
							GAC Asp	960
							GCT Ala 335	1008
							CTA Leu	1056

CGGGCTTTTT TTTAGGCCTA

1604

											AGT Ser					1104
											GCG Ala 380					1152
CAC His 385	AAA Lys	ACG Thr	CAT His	GCT Ala	CAC His 390	AAA Lys	TGC Cys	GAC Asp	ATC Ile	ACC Thr 395	CTG Leu	CAG Gln	GAA Glu	ATC Ile	ATC Ile 400	1200
											CTG Leu					1248
ACG Thr	GTA Val	ACC Thr	GAC Asp 420	ATC Ile	TTC Phe	GCT Ala	GCA Ala	TCC Ser 425	AAA Lys	AAC Asn	ACC Thr	ACT Thr	GAA Glu 430	AAA Lys	GAA Glu	1296
ACC Thr	Phe	TGC Cys 435	CGT Arg	GCA Ala	GCA Ala	ACT Thr	GTT Val 440	CTG Leu	CGT Arg	CAG Gln	TTC Phe	TAC Tyr 445	TCC Ser	CAC His	CAC His	1344
											CAG Gln 460					1392
											GAC Asp					1440
GGC Gly	CTG Leu	GCT Ala	GGC Gly	CTG Leu 485	AAC Asn	TCC Ser	TGT Cys	CCG Pro	GTT Val 490	AAA Lys	GAA Glu	GCT Ala	AAC Asn	CAG Gln 495	TCG Ser	1488
											ATC Ile					1536
	TCT Ser					TGAG	SAGCI	CA C	TACI	TAGCO	CC GC	CTA	ATGAG	3		1584

- 28 -

Claims

- Use of a molecule which a) specifically binds under physiological conditions to an interleukin-4 (IL-4) receptor expressed on a peripheral blood mononuclear cell
 (PBMC) of an animal, and b) is capable of decreasing the viability of said PBMC in the preparation of a medicament for desensitizing an animal to an allergen.
 - 2. The use of claim 1, wherein said molecule kills said PBMC following binding to said IL-4 receptor.
- 3. The use of claim 1, wherein said molecule is a hybrid molecule comprising a first and a second portion joined together covalently, said first portion comprising a moiety capable of decreasing cell viability and said second portion comprising a moiety capable of specifically binding to said IL-4 receptor under physiological conditions.
 - 4. The use of claim 3, wherein said second portion comprises all or a binding portion of an antibody specific for said IL-4 receptor.
- 5. The use of claim 3, wherein said second portion comprises all or a binding portion of IL-4.
 - 6. The use of claim 3, wherein said first portion comprises an enzymatically-active segment of a polypeptide toxin.

- 29 -

- 7. The use of claim 6, wherein said polypeptide toxin is diphtheria toxin, Pseudomonas exotoxin A, ricin, Shiga toxin, Shiga-like toxin-I, Shiga-like toxin II, Shiga-like toxin II, Shiga-like toxin II, E. coli LT, Salmonella LT, cholera toxin, C3 toxin, pertussis toxin, tetanus toxin, abrin, modeccin, volkensin, viscumin, alorin, saporin, or gelonin.
 - 8. The use of claim 7, wherein said polypeptide toxin is diphtheria toxin.
- 9. The use of claim 6, wherein said segment does not possess a generalized eukaryotic cell-binding activity.
- 10. The use of claim 9, wherein said segment comprises fragment A of diphtheria toxin and a portion of fragment B of diphtheria toxin.
 - 11. The use of claim 10, wherein said segment comprises DAB389.
 - 12. The use of claim 11, wherein said molecule is $\mathtt{DAB}_{\mathtt{389}}\mathtt{IL-4}$.
- 20 13. The use of claim 10, wherein said second portion comprises an IL-4-receptor-binding portion of an antibody specific for said IL-4 receptor.
- 14. Use of a molecule which is capable of specifically binding to an IL-4 receptor expressed on the 25 surface of a B cell, and which is capable of decreasing the viability of said B cell in the preparation of a

- 30 -

medicament for inhibiting the antibody heavy-chain class switching of a B cell.


- 15. The use of claim 14, wherein said molecule is a hybrid molecule comprising a first and a second portion 5 joined together covalently, said first portion comprising a moiety capable of decreasing cell viability and said second portion comprising a moiety capable of specifically binding to said IL-4 receptor under physiological conditions.
- 16. The use of claim 15, wherein said second portion comprises all or a binding portion of an antibody specific for said IL-4 receptor.
 - 17. The use of claim 15, wherein said second portion comprises all or a binding portion of IL-4.
- 18. The use of claim 15, wherein said first portion comprises an enzymatically-active segment of a polypeptide toxin.
- The use of claim 18, wherein said polypeptide toxin is diphtheria toxin, Pseudomonas exotoxin A, ricin,
 Shiga toxin, Shiga-like toxin-I, Shiga-like toxin II,
 Shiga-like toxin II_v, E. coli LT, Salmonella LT, cholera toxin, C3 toxin, pertussis toxin, tetanus toxin, abrin, modeccin, volkensin, viscumin, alorin, saporin, or gelonin.
- 25 20. The use of claim 19, wherein said polypeptide toxin is diphtheria toxin.


- 31 -

- 21. The use of claim 20, wherein said segment comprises fragment A of diphtheria toxin and a portion of fragment B of diphtheria toxin.
- 22. The use of claim 21, wherein said segment 5 comprises DAB₃₈₉.
 - 23. The use of claim 22, wherein said molecule is $\mathtt{DAB}_{389}\mathtt{IL-4}$.
- 24. The use of claim 1, further comprising the use of a second molecule which a) specifically binds


 10 under physiological conditions to an interleukin-2 (IL-2) receptor expressed on said PBMC or a second PBMC of said animal, and b) is capable of decreasing the viability of the PBMC to which it binds in the preparation of said medicament.
- 15 25. The use of claim 1, further comprising the use of a second molecule which a) specifically binds under physiological conditions to an interleukin-6 (IL-6) receptor expressed on said PBMC or a second PBMC of said animal, and b) is capable of decreasing the viability of the PBMC to which it binds in the preparation of said medicament.


(PAGE 1 OF 8)






(PAGE 3 OF 8)






(PAGE 5 OF 8)



(PAGE 6 OF 8)



1350 AAA CAC GTA ACC GAC Val Thr Asp Leu Asn 1390 1300 SphI CAC His CTG ACC His $\mathbf{L}\mathbf{L}\mathbf{C}$ CAC His Glu GAA ACT Thr CTG ACG Leu Thr 1160 1250 LysTCC Lys Ser AAA AAA CAG AAA ATC GAA GAA Glu CAG Gln TTC TAC Tyr His 1290 1380 1200 G1yTGC ACC ACT Gln Phe Cys Thr Thr Thr 1240 1150 ACC Pro Thr CAG ၅၁၁ TCT Leu Ser CAG Gln AAA AAC Lys Asn CGT ACT CTG 1190 1280 Leu Leu CTGCTGTAT TyrLys $\mathbf{I}^{\mathbf{CC}}$ Ser GTTLeu GCG ACC Thr CAG AAA Val Arg Pro Ala 1230 Gln ACT GCA Thr TGC CGI CCC GCA Glu Asp CGC GAC Arg GCT Arg Ala Tyr Asn CTG ACC CGT GCA Leu

FIG. 1 (PAGE 7 OF 8)




FIG. 1 (PAGE 8 OF 8)

TCC Ser

Ser

TGT

AAA Lys

 \mathbf{LCT}

Ser

TAC

AAA Lys

GAA

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/01034

1	SSIFICATION OF SUBJECT MATTER		
	:A61K 45/05, 39/00, 37/02 :424/85.1, 85.2, 85.8, 88; 514/2		
	o International Patent Classification (IPC) or to both	national classification and IPC	
B. FIEI	LDS SEARCHED		
Minimum d	ocumentation searched (classification system followed	d by classification symbols)	
U.S. :	424/85.1, 85.2, 85.8, 88; 514/2		
Documentat	ion searched other than minimum documentation to the	e extent that such documents are included	in the fields searched
н .			
Electronic d	lata base consulted during the international search (na	ame of data base and, where practicable	, search terms used)
	SES: US PTO-PAS, Medline TERMS: Interleukin-4, -6; Allergy; IgM, Immunog	globulin, Switch	
C. DOC	UMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where ar	opropriate, of the relevant passages	Relevant to claim No.
Y	Proceedings of the National Academ Volume 86, issued June 1989, M. Ogo of a recombinant fusion protein Pseudomonas exotoxin", pages 4215-14219.	ata et al., "Cytotoxic activity between interleukin 4 and	1-25
Y	European Journal of Immunology, Vo Prinz et al., "Allergen-directed expres (CD23) on human T lymphocytes is m interferon-gamma", pages 1259-64, esp	ssion of Fc receptors for IgE odulated by interleukin 4 and	1-13, 24, 25
		•	
		,	
X Furth	ner documents are listed in the continuation of Box C	Sce patent family annex.	
	ecinl categories of cited documents:	"I" later document published after the inte	ation but cited to understand the
	cument defining the general state of the art which is not considered be part of particular relevance	principle or theory underlying the inv	ention
	lier document published on or after the international filing date	'X' document of particular relevance; the	
cit	current which may throw doubts on priority claim(s) or which is ed to establish the publication date of another citation or other	when the document is taken alone 'Y' document of particular relevance; th	e claimed invention serves be
O do	ecial reason (as specified) cument referring to an oral disclosure, use, exhibition or other cans	considered to involve an inventive combined with one or more other suc being obvious to a person skilled in the	step when the document is h documents, such combination
	cument published prior to the international filing date but later than priority date claimed	'&' document member of the same patent	family
Date of the	actual completion of the international search	Date of mailing of the international sea	arch report
19 April 1	1993	30 APR	1993
Commissio Box PCT	nailing address of the ISA/US ner of Patents and Trademarks n, D.C. 20231	Authorized officer (Line) DAVID L. FITZGERALD	Kung for
_	o. NOT APPLICABLE	Telephone No. (703) 308-0196	

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/01034

C (Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	EMBO Journal, Volume 8, Number 2, issued 1989, C. Esser et al., "Rapid induction of transcription of unrearranged s-gamma 1 switch regions in activated murine B cells by interleukin 4", pages 483-88, especially the abstract.	14-23
Y	Kidney International, Volume 35, issued 1989, T. B. Strom et al., "Toward more selective therapies to block undesired immune responses", pages 1026-33, see the entire document.	24, 25
Y	Proceedings of the National Academy of Sciences of the USA, Volume 85, issued December 1988, C. B. Siegall et al., "Cytotoxic activity of an interleukin 6- <u>Pseudomonas</u> exotoxin fusion protein on human myeloma cells", pages 9738-42, especially the abstract.	25
	***	*
		*(-
		£* * * * *
	*	Ψ.
		*
		*
		Y
		, · · ·
		* V
		e e
		*
		* *
		* "